NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of AngioDynamics, Inc. (NASDAQ:ANGO) investors concerning whether the company’s officers and board of directors violated their fiduciary duties.
AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. The investigation relates to the company’s alleged misleading statements regarding its financial performance, and investor losses related to recent AngioDynamics disclosures. On October 8, 2015, after the market closed, the company announced poor fiscal first quarter 2016 financial results. AngioDynamics attributed the results to “negative year-over-year revenue growth due to tough comparisons to the prior year brought on by fiscal 2015’s voluntary withdrawal of our Morpheus PICC line and foreign currency headwinds.”
On this news, shares of AngioDynamics stock declined $0.88, or 7.1%, to close at $12.23 per share on October 9, 2015, thereby injuring investors.
If you are an AngioDynamics stockholder and have information that could assist in this investigation, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.